Last reviewed · How we verify
NCT06973681
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
Phase 2 trial testing BGM0504 in Overweight or Obesity in 120 participants. Completed in 13 September 2024.
13 September 2024
Quick facts
| Lead sponsor | BrightGene Bio-Medical Technology Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 13 October 2023 |
| Primary completion | 13 September 2024 |
| Estimated completion | 13 September 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- BGM0504
- BGM0504
- BGM0504
- Placebo
Conditions studied
- Overweight or Obesity — all drugs for Overweight or Obesity →
Sponsor
BrightGene Bio-Medical Technology Co., Ltd. — full company profile →
Who can join
Adults 18 to 60, any sex, with Overweight or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06973681
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BGM0504
Trials testing the same drug.
- NCT07166081 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight o · Phase 1 · recruiting
- NCT07064486 — A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia · Phase 3 · recruiting
- NCT06929156 — A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function · Phase 1 · completed
- NCT06911203 — A Study of BGM0504 in Participants With Obesity · Phase 2 · recruiting
- NCT06920056 — A Study of BGM0504 in Overweight or Obese Participants · Phase 1 · completed
Other recruiting trials for Overweight or Obesity
Currently open trials in the same condition.
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07431086 — Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US · Phase 2 · recruiting
- NCT07294235 — A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants · Phase 1 · recruiting
- NCT07224399 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multi · Phase 1 · recruiting
- NCT07170319 — A Study of IBI3032 in Chinese Participants With Overweight or Obesity · Phase 1 · active not recruiting
Other BrightGene Bio-Medical Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT07382908 — Bioequivalence Study of BGM0504 Injection · Phase 1 · recruiting
- NCT07294235 — A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants · Phase 1 · recruiting
- NCT07239973 — A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects · Phase 1 · recruiting
- NCT07224399 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multi · Phase 1 · recruiting
- NCT07166081 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight o · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06973681 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BrightGene Bio-Medical Technology Co., Ltd.
- Last refreshed: 15 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06973681.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing